Published by Iain Gilbert on 14th September 2026
(Sharecast News) - Drugmaker GSK reported two major advances in its oncology pipeline on Monday, as new data showed its B7‑H3 antibody‑drug conjugate Ris‑Rez delivered a significant survival benefit in relapsed small cell lung cancer, while registrational results for Jideytro supported a potential move into first‑line ROS1‑positive non‑small cell lung cancer.